3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder which affects the nerve-muscle junction. The major symptoms of LEMS are progressive muscle weakness. Many patients experience other symptoms like dry mouth or impotence. Congenital Myasthenia (CM) is an inherited disorder with similar affects and symptoms.
3,4-Diaminopyridine (DAP) is an experimental drug that has improved strength in some subjects with (LEMS). There are no other accepted treatments for LEMS and DAP has relatively few side effects.
Lambert-Eaton Myasthenic Syndrome (LEMS)
Congenital Myasthenia (CM)
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenia|
Please refer to this study by its ClinicalTrials.gov identifier: NCT02012933
|Contact: Diana Dimitrova, PhDemail@example.com|
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States, 97239|
|Contact: Diana Dimitrova, PhD 503-494-7269 firstname.lastname@example.org|
|Principal Investigator: Tessa Marburger, MD|
|Sub-Investigator: Julie Khoury, MD|